Literature DB >> 3463241

Characteristics of vincristine resistance in vincristine resistant human myelogenous leukemia K562.

T Tsuruo, T Oh-Hara, H Saito.   

Abstract

A stable vincristine (VCR)-resistant variant (K562/VCR) was established from human myelogenous leukemia K562 by continuous exposure of the cells with increasing concentration of VCR up to 30 nM, followed by the maintenance of the cells in the presence of 30 nM of VCR for 6 months. In four clones with different VCR sensitivity, the extent of VCR-resistance and Adriamycin-resistance was always parallel among the clones, indicating a tight relationship between VCR- and ADM-resistance mechanisms. The clones accumulated significantly low amounts of VCR in the cells. The amounts of VCR in the clones and K562/VCR were inversely related to the extent of resistance of the cells. The rate and the extent of VCR efflux from the cells were parallel to the extent of resistance of the cells to VCR. One VCR-resistant clone, KV-11, was found to possess diminished amounts of beta-tubulin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3463241

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Decreased expression of the amplified mdr1 gene in revertants of multidrug-resistant human myelogenous leukemia K562 occurs without loss of amplified DNA.

Authors:  Y Sugimoto; I B Roninson; T Tsuruo
Journal:  Mol Cell Biol       Date:  1987-12       Impact factor: 4.272

2.  Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.

Authors:  T Tsuruo; T Matsuzaki; M Matsushita; H Saito; T Yokokura
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  A benzophenazine derivative, N-beta-dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxy-benzo[a]phenazine-6-carboxamide, as a new antitumor agent against multidrug-resistant and sensitive tumors.

Authors:  T Tsuruo; M Naito; R Takamori; S Tsukahara; J Yamabe-Mitsuhashi; A Yamazaki; T Oh-hara; Y Sudo; S Nakaike; T Yamagishi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.

Authors:  Francesco Ceppi; Chloé Langlois-Pelletier; Vincent Gagné; Julie Rousseau; Claire Ciolino; Samanta De Lorenzo; Kojok M Kevin; Diana Cijov; Stephen E Sallan; Lewis B Silverman; Donna Neuberg; Jeffery L Kutok; Daniel Sinnett; Caroline Laverdière; Maja Krajinovic
Journal:  Pharmacogenomics       Date:  2014-06       Impact factor: 2.533

5.  Reversal of multidrug resistance by an immunosuppressive agent FK-506.

Authors:  M Naito; T Oh-hara; A Yamazaki; T Danki; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Chemomodulation of drugs involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type.

Authors:  A Reichle; H Diddens; F Altmayr; J Rastetter; R Andreesen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Reversal of multidrug resistance by novel nitrophenyl pyrones, SNF4435C and D.

Authors:  K Kurosawa; K Takahashi; E Tsuda; A Tomida; T Tsuruo
Journal:  Jpn J Cancer Res       Date:  2001-11

8.  Characterisation of a navelbine-resistant bladder carcinoma cell line cross-resistant to taxoids.

Authors:  V Debal; N Allam; H Morjani; J M Millot; D Braguer; F Breillout; M Manfait
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.